Ann: Third complete response in PTX-200 AML Trial, page-207

yes have seen a lot trapped with NHL, IMU, SDX lots of companies making 'breakthroughs'. Only time will tell which biotech story and research will prevail. Right now investors are fixated on the successful 'eradication' of patient's tumour -total 3 out of 15 trialled patients, but what happened to the other 12 patients and those holders arguing it is a 100% success rate? One would conclude very easily that if the trial consists of only 3 patients and that all 3 returned with total eradication of the cancer than yes 100% however PTX failed to mention what had transpired with the other 12 patients in the trial. It is by all means a fantastic outcome for 'some' patients with refractory AML whilst others must seek an alternate route since PTX-200 was ineffective. Still a speculative buy, but as the saying goes 'you've got to be in it to win it'.

'Three of a total of 15 patients experienced complete responses in the study in relapsed orrefractory AML patients, which is a difficult to treat cancer population. The three patients hadbetween 25-35mg/m2 PTX-200, together with 200-400mg/m2 cytarabine'.